Latest news with #KymeraTherapeutics
Business Insider
3 hours ago
- Business
- Business Insider
Stifel Nicolaus Keeps Their Buy Rating on Kymera Therapeutics (KYMR)
analyst Alex Thompson CFA maintained a Buy rating on Kymera Therapeutics (KYMR – Research Report) yesterday and set a price target of $68.00. The company's shares closed yesterday at $47.66. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Thompson CFA covers the Healthcare sector, focusing on stocks such as Kymera Therapeutics, Oruka Therapeutics, and Travere Therapeutics. According to TipRanks, Thompson CFA has an average return of -2.8% and a 45.45% success rate on recommended stocks. In addition to Stifel Nicolaus, Kymera Therapeutics also received a Buy from UBS's Eliana Merle in a report issued on June 3. However, on May 30, Bank of America Securities maintained a Hold rating on Kymera Therapeutics (NASDAQ: KYMR). The company has a one-year high of $53.27 and a one-year low of $19.45. Currently, Kymera Therapeutics has an average volume of 856.8K.
Yahoo
3 days ago
- Business
- Yahoo
Why Kymera Therapeutics, Inc. (KYMR) Skyrocketed On Monday
We recently published a list of . In this article, we are going to take a look at where Kymera Therapeutics, Inc. (NASDAQ:KYMR) stands against other top-performing stocks on Monday. Kymera Therapeutics saw its share prices surge by 45.51 percent on Monday to end at $43.13 apiece following the early-stage success of its drug candidate for the treatment of the moderate to severe form of eczema. In a statement, Kymera Therapeutics, Inc. (NASDAQ:KYMR) said that its primary objective to demonstrate that its drug candidate, KT-621, could achieve robust STAT6 degradation in blood and skin went 'well beyond our expectations.' A biopharmaceutical laboratory with scientists in lab coats working on medicines. The first phase of the trial enrolled 118 healthy volunteers who tested the safety and tolerability of KT-621. 'Building from the compelling preclinical data … is a powerful demonstration of what we believe is an impeccable translation into humans,' it said. If the drug succeeds all trials and secures regulatory approvals, it would rival Sanofi and Regeneron's blockbuster therapy, Dupixent. Following the trial results, Kymera Therapeutics, Inc. (NASDAQ:KYMR) earned a 'buy' recommendation and a higher price target of $51 from Bank of America, versus $44 previously. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Business Insider
3 days ago
- Business
- Business Insider
Kymera Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Kymera Therapeutics (KYMR) to Overweight from Equal Weight with a price target of $79, up from $49. The company reported Phase 1 data for STAT6 degraded KT-621 thtat the firm believes addressed key questions on safety and target knockdown, the analyst tells investors in a research note. The firm added that the data increases its confidence in KT-621's ability to compete across large immunology and inflammation indications and in Kymera's platform more broadly. Confident Investing Starts Here:
Business Insider
3 days ago
- Business
- Business Insider
Truist Financial Reaffirms Their Buy Rating on Kymera Therapeutics (KYMR)
In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Kymera Therapeutics (KYMR – Research Report), with a price target of $53.00. Confident Investing Starts Here: According to TipRanks, Devarakonda is an analyst with an average return of -5.9% and a 32.60% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Cytokinetics, Regeneron, and Scholar Rock Holding. In addition to Truist Financial, Kymera Therapeutics also received a Buy from Citi's Geoff Meacham in a report issued today. However, yesterday, Morgan Stanley maintained a Hold rating on Kymera Therapeutics (NASDAQ: KYMR). Based on Kymera Therapeutics' latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $22.1 million and a GAAP net loss of $65.58 million. In comparison, last year the company earned a revenue of $10.29 million and had a GAAP net loss of $48.56 million Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KYMR in relation to earlier this year. Most recently, in March 2025, Jeremy Chadwick, the COO of KYMR sold 1,383.00 shares for a total of $42,103.92.
Yahoo
4 days ago
- Business
- Yahoo
Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response
Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine. The findings significantly surpassed the company's expectations, demonstrating robust STAT6 degradation and a favorable safety profile, thereby derisking the program, the company said in a press release. Pharmacokinetics (PK): KT-621 demonstrated a favorable plasma PK profile after single and multiple doses. Rapid absorption was demonstrated with a median tmax of 2-4 hours and a mean half-life of 9-36 hours. There was a dose-proportional increase in exposure after multi-dosing, and a steady state was achieved by Day (PD): KT-621 demonstrated rapid, deep, and prolonged STAT6 degradation in blood after single doses of KT-621 and in blood and skin after multiple doses of KT-621. STAT6 levels in blood and skin were measured. Complete degradation within a cohort is defined as either a mean reduction of ≥95% or, when most subjects' STAT6 levels are reduced below the Lower Limit of Quantification (LLOQ), or both. In SAD, maximal degradation was achieved in blood as quickly as the first collected timepoint of 4 hours after a single dose, with mean STAT6 degradation reaching >90% across all SAD doses starting at 6.25 mg. All SAD cohorts at 75 mg or greater doses achieved >95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects. In MAD, STAT6 degradation was observed in blood at the first timepoint measured (8 hours) for doses above 1.5 mg. Steady-state, complete degradation, associated with STAT6 reductions below the LLOQ in the majority of subjects, was achieved at doses ≥50 mg, with recovery starting as early as 4 days after the last dose. In MAD, robust STAT6 degradation was observed in the skin at the first timepoint measured (Day 7) for doses above 1.5 mg. Steady-state, complete degradation, associated with ≥95% mean STAT6 degradation with STAT6 levels below LLOQ in multiple subjects, was achieved at doses ≥50 mg. Th2 Biomarkers: TARC reduction was observed for all KT-621 dose groups, with a median reduction of up to 37% at Day 14. The company says the results are comparable or superior to what was seen in the Sanofi SA (NASDAQ:SNY)/Regeneron Pharmaceuticals Inc's (NASDAQ:REGN) Dupixent (dupilumab) healthy volunteer study. The safety profile of KT-621 was undifferentiated from that of the placebo. The company's KT-621 BroADen Phase 1b trial in moderate to severe atopic dermatitis patients is ongoing, with data expected to be reported in the fourth quarter of 2025. Two parallel Phase 2b trials in atopic dermatitis and asthma will start in 4Q25 and 1Q26, respectively. Price Action: KYMR stock was trading higher by 30.2% to $38.58 at last check Monday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Kymera Therapeutics Says Atopic Dermatitis Potential Matches Sanofi/Regeneron's Blockbuster Dupixent In Early Biomarker Response originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
